Abstract
Chronic urticaria is a common and recurrent allergic disease in dermatology. Antihistamines are the first-line treatment of chronic urticaria, but nearly half of patients show poor responses to antihistamines. Complicated pathogenesis of chronic urticaria, including imbalance of Th1/Th2 cell subsets and abnormality of inflammatory mediators, IgE and anti-FceRⅠ antibody, may be one of the important reasons why chronic urticaria is hard to cure. Biological agents can selectively regulate or inhibit immune abnormality, and have become a new approach to the treatment of chronic urticaria and other urticaria-related skin diseases. Related biological agents mainly include BCG-polysaccharide nucleic acid, gamma globulins, tumor necrosis factor (TNF) -α inhibitors, interleukin (IL) -1 blockers, rituximab, omalizumab, and so on, and play important roles in the treatment of chronic urticaria. Omalizumab, a kind of anti-IgE monoclonal antibody, has a favorable benefit/risk ratio and good tolerability, and is considered to be one of the ideal biological agents for the treatment of chronic urticaria. Key words: Urticaria; Biological agents; Antibodies, monoclonal; Rituximab; Omalizumab
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Dermatology and Venereology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
